UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial
Authors:
- Zhiguang ZhouZZZhiguang Zhou
- Zhifeng ChengZCZhifeng Cheng
- Ping JinPJPing Jin
- Guoping YangGYGuoping Yang
- Haifang WangHWHaifang Wang
- Bimin ShiBSBimin Shi
- Qijuan DongQDQijuan Dong
- Xiaoxia ShiXSXiaoxia Shi
- Xiaoguang ShiXSXiaoguang Shi
- Hongyan ShuHSHongyan Shu
- Wenli SunWSWenli Sun
- Chongbing HuangCHChongbing Huang
Open Access
- 8 October 2026
- journal article
- Published by Elsevier in Cell Metabolism
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefitsThe Lancet, 2026
- GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesitySaudi Pharmaceutical Journal, 2025
- Projecting Global Trends and Inequalities in Adult Overweight and Obesity, 2023–2040: Findings From the NCD‐RisC DatabaseObesity, 2025
- Gastrointestinal Motility Effects of GLP-1 Receptor AgonistsCurrent Gastroenterology Reports, 2025
- Forecasting the global obesity epidemic through 2050The Lancet, 2025
- Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021The Lancet, 2025
- National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050The Lancet, 2024
- A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity ManagementEndocrine Practice, 2023
- Glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypeptide, and glucagon receptor poly‐agonists: a new era in obesity pharmacotherapyObesity, 2022
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1Cell Metabolism, 2018